<DOC>
	<DOCNO>NCT01832506</DOCNO>
	<brief_summary>This Japanese multicenter , open-label , Phase 1 study evaluate safety efficacy MSC2156119J subject malignant solid tumor refractory standard therapy effective standard therapy applicable .</brief_summary>
	<brief_title>A Japanese Phase 1 Trial c-Met Inhibitor MSC2156119J Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>A subject histologically cytologically confirm diagnosis malignant solid tumor refractory standard therapy effective standard therapy applicable An archived tumor tissue available biopsy tumor tissue newly perform A Japanese male female , age great equal ( &gt; = ) 20 year A subject read Subject Information Sheet understood detail clinical trial , willing able give his/her inform consent . A female childbearing potential must negative blood pregnancy test result screen period . A female subject childbearing potential must willing avoid pregnancy use adequate method contraception Life expectancy least 3 month Other inclusion criterion apply Known Human immunodeficiency virus ( HIV ) positivity , active hepatitis C , active hepatitis B Presence liver fibrosis liver cirrhosis histologically diagnose Signs symptom suggest transmissible spongiform encephalopathy Received major surgery within 6 week Day 1 Cycle 1 Known drug abuse alcohol abuse Known hypersensitivity trial treatment ingredient Hematological test abnormality Renal impairment define protocol Liver dysfunction define protocol History presence central nervous system metastasis History presence disease condition may hamper compliance absorption investigational medicinal product ( IMP ) due difficulty swallow absorption Poor performance status Eastern Cooperative Oncology Group Performance status ( ECOG PS ) &gt; = 2 Received anticancer therapy day Received extensive prior radiotherapy irradiate 30 percent bone marrow Received radiotherapy within 4 week Day 1 Cycle 1 Pregnancy lactation period History receive treatment cMet signal pathway inhibitor Participation another interventional clinical trial within past 30 day Day 1 Cycle 1 Other significant disease Investigator 's opinion would exclude subject trial Legal incapacity limit legal capacity Other exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>MSC2156119J</keyword>
	<keyword>c-Met inhibitor</keyword>
	<keyword>Japanese</keyword>
	<keyword>Phase 1</keyword>
</DOC>